Innate Resistance to HIV by CCR5-delta 32 in Serodiscordant Couples in Kinshasa Hospitals
DOI:
https://doi.org/10.14738/bjhr.1203.17620Keywords:
CCR5 delta-32, Discordant couples, Innate HIV resistance, KinshasaAbstract
Background: Worldwide, around 1% of people remain free of Human Immunodeficiency Virus infection without receiving Antiretroviral Therapy. This innate resistance is genetic or immunological in origin, and one of the main mechanisms reported to date is the homozygous Δ32 mutation of the CCR5 gene. Objective: Search for the delta 32 mutation of the CCR5 gene in HIV discordant couples in Kinshasa. Methods: Descriptive cross-sectional study of different HIV serodiscordant heterosexual couples followed at CHME Monkole and CS Sainte Anne in Kinshasa, DRC, from November 2021 to June 2022. Data were collected from information sheets drawn up by the research team and from computerized patient records in the Infectious Diseases Unit of these centers. Blood was collected from a peripheral vein in an EDTA tube. It was used for biomolecular analyses. Conventional PCR was performed to detect the CCR5-delta 32 mutation. Results: Of a total of 514 heterosexual couples followed for HIV, 472 were sero-concordant and 42 were HIV-serodiscordant, representing a discordance frequency of 8.2%. Eighteen discordant couples (3.5%) consented to participate in the present study. The heterozygous CCR5-delta 32 mutant genotype was found in 11.1% of HIV-negative partners. The chi-square test did not show a significant relationship between serodiscordance and the CCR5-delta 32 mutation. Conclusion: The frequency of HIV-discordant couples and of heterozygous CCR5-delta 32 mutation is significant. CCR5-delta 32 may account for the serodiscordance of couples in the DRC.
References
Rugeles MT, Velilla PA, Montoya CJ. Mechanisms of human natural resistance to HIV : A summary of ten years of research in the Colombian population. Biomédica. 2011;31(2):269–280.
Sida et VIH : À quand la guérison ? Inserm, La science pour la santé. 2017. https://www.inserm.fr/dossier/sida-et-vih/. Accessed 4 October 2021.
P. BONNARD JBG-S et GP. Principes des traitements des patients infectés par le VHI. Antibiotiques. 2005;7(2):77–86.
Berre S, Gaudin R, Cunha de Alencar B, Desdouits M, Chabaud M, Naffakh N, et al. CD36-specific antibodies block release of HIV-1 from infected primary macrophages and its transmission to T cells. J Exp Med. 2013;210(12):2523–2538.
Kulkarni PS, Butera ST DAC. Resistance to HIV-1 infection : lessons learned from studies of highly exposed persistently seronegative (HEPS) individualso Title. AIDS Rev. 2003;5:87–103.
A. Eberhard, B. Ponceau, F. Biron BV. Les mécanismes de résistance à la transmission sexuelle du VIH-1. Médecine Mal Infect. 2005;35:517–524.
Decoster JL et A. VIH. FLM. 2006.
Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber C-M, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382(6593):722–725.
et al Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O’Brien S, Andrieu JM. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol. 1999;162:6942–6946.
et al MacDonald KS, Embree J, Njenga S, Nagelkerke NJ, Ngatia I, Mohammed Z. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J Infect Dis. 1998;177:551–556.
et al MacDonald KS, Embree JE, Nagelkerke NJ, Castillo J, Ramhadin S, Njenga S. The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission. J Infect Dis. 2001;183:503–506.
Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P SJ. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004;427:848–853.
Sadeghpour S, Khodaee S, Rahnama M, Rahimi H, Ebrahimi D. Human APOBEC3 Variations and Viral Infection. Viruses. 2021;13(7):1366.
Stavrou S, Ross SR. APOBEC3 proteins in viral immunity. J Immunol. 2015;195(10):4565–4570.
MacMillan AL, Kohli RM, Ross SR. APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription. J Virol. 2013;87(9):4808–4817.
McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP WSM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 1995;96:456–464.
SM I. Trappin-2: Discovery of a Novel Inhibitor of HIV-1 Highly Elevated in HIV-1-Resistant Sex Workers. In: XVI International AIDS conference. 2006. Toronto.
et al. Trabattoni D, Caputo SL MG. Human alpha Defensin in HIV-Exposed But Uninfected Individuals. J Acquir Immune Defic Syndr. 2004;35:455–463.
Quinones-Mateu ME, Lederman MM FZ. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS. 2003;17:F39--48.
Heeney JL, Dalgleish AG WRA. Origins of HIV and the evolution of resistance to AIDS. Science (80- ). 2006;313:462–466.
Gallo RC LP. Chemokines and HIV infection. Curr Opin Infect Dis. 1997;10:12–17.
Bleul CC, Farzan M CH. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;382:829–833.
Stark GR, Kerr IM, Williams BR, Silverman RH SRD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227–264.
Montoya CJ, Velilla PA, Chougnet C, Landay AL RMT. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol. 2006;120:138–146.
Walker CM, Moody DJ, Stites DP LJA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science (80- ). 1986;234:1563–1566.
et al Patterson BK, Behbahani H, Kabat WJ, Sullivan Y, O’Gorman MR, Landay A. Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women. J Clin Invest. 2001;107:287–294.
Lee-Huang S, Huang PL, Sun Y, Kung HF, Blithe DL CHC. Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin. Proc Natl Acad Sci U S A. 1999;96:2678–2681.
BL S. Understanding the ‘“lucky few”’: the conundrum of HIV-exposed, seronegative individuals. Curr HIV/AIDS Rep. 2006;3:26–31.
Shrestha S, Strathdee SA GN. Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. J Infect Dis. 2006;193:16–26. 211
Hirbod T BK. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women (Review). J Intern Med. 2007;262:44–58.
Marmor M, Hertzmark K, Thomas SM, Halkitis PN, Vogler M. Resistance to HIV infection. J urban Heal. 2006;83:5–17.
Fath-Elrahman MH, Alkarsany M, Nour BYM, Abakar AD, Mhammed AE, Elzaki SG, et al. Rating of CCR5-Delta 32 Homozygous Mutation in Sudanese HIV Patients and Sex Workers. World J AIDS. 2022;12(2):55–64.
Danboyi DA. Molecular Detection of CCR5 D32 Allele Gene Among Discordant HIV-Infected Couples in Kaduna State, Nigeria. 2022.
Berg MG, Olivo A, Harris BJ, Rodgers MA, James L, Mampunza S, et al. A high prevalence of potential HIV elite controllers identified over 30 years in Democratic Republic of Congo. EBioMedicine. 2021;65:103258.
Carpenter LM, Kamali A, Ruberantwari A, Malamba SS, Whitworth JAG. Rates of HIV-1 transmission within marriage in rural Uganda in relation to the HIV sero-status of the partners. Aids. 1999;13(9):1083–1089.
Matovu JKB. Preventing HIV transmission in married and cohabiting HIV-discordant couples in sub-Saharan Africa through combination prevention. Curr HIV Res. 2010;8(6):430–440.
Curran K, Baeten JM, Coates TJ, Kurth A, Mugo NR, Celum C. HIV-1 prevention for HIV-1 serodiscordant couples. Curr HIV/AIDS Rep. 2012;9:160–170.
Jiao X, Nawab O, Patel T, Kossenkov A V, Halama N, Jaeger D, et al. Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-OncologyTargeting CCR5 for Cancer. Cancer Res. 2019;79(19):4801–4807.
Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996;35(11):3362–3367.
Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, et al. CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer CellsAntimetastatic Effect of CCR5 Antagonist. Cancer Res. 2012;72(15):3839–3850.
Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381(6584):667–673.
Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997;185(9):1681–1692.
Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, et al. CCR5 receptor antagonists block metastasis to bone of v-Src oncogene–transformed metastatic prostate cancer cell lines. Cancer Res. 2014;74(23):7103–7114.
Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86(3):367–377.
Rottman JB, Ganley KP, Williams K, Wu L, Mackay CR, Ringler DJ. Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am J Pathol. 1997;151(5):1341.
de Silva E, Stumpf MPH. HIV and the CCR5-Δ32 resistance allele. FEMS Microbiol Lett. 2004;241(1):1–12.
Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science (80- ). 1996;273(5283):1856–1862.
Scutti S. Why some people are naturally immune to hiv. Med Dly. 2014;180(1–2):29–48.
Ronsard L, Sood V, Yousif AS, Ramesh J, Shankar V, Das J, et al. Genetic polymorphisms in the open reading frame of the CCR5 gene from HIV-1 seronegative and seropositive individuals from national capital regions of india. Sci Rep. 2019;9(1):1–9.
Benkirane M, Jin D-Y, Chun RF, Koup RA, Jeang K-T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32. J Biol Chem. 1997;272(49):30603–30606. 212
Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, et al. The role of a mutant CCR5 allele in HIV–1 transmission and disease progression. Nat Med. 1996;2(11):1240–1243.
Michael NL, Louie LG, Rohrbaugh AL, Schultz KA, Dayhoff DE, Wang CE, et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med. 1997;3(10):1160–1162.
Primer-BLAST. https://www.ncbi.nlm.nih.gov/tools/primer-blast/.
National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/gene/1234.
Habte E, Yami A, Alemseged F, Abdissa Y, Deribe K, Memiah P, et al. Predictors of HIV serodiscordance among couples in southwestern Ethiopia. J Int Assoc Provid AIDS Care. 2015;14(3):234–240.
De Walque D. Sero‐discordant couples in five African countries: implications for prevention strategies. Popul Dev Rev. 2007;33(3):501–523.
Kaiser R, Bunnell R, Hightower A, Kim AA, Cherutich P, Mwangi M, et al. Factors associated with HIV infection in married or cohabitating couples in Kenya: results from a nationally representative study. PLoS One. 2011;6(3):e17842.
Tadesse M. Assessment of HIV discordance and associated risk factors among couples receiving HIV test in Dilla, Ethiopia. BMC Res Notes. 2014;7(1):1–12.
Gokaba JM. Sérologie discordante du VIH/sida et vie des couples en République du Congo: profil sociodémographique, comportements, facteurs de survie et prise en charge. 2020. https://theses.hal.science/tel-03160588/.
Osinde MO, Kaye DK, Kakaire O. Sexual behaviour and HIV sero-discordance among HIV patients receiving HAART in rural Uganda. J Obstet Gynaecol (Lahore). 2011;31(5):436–440.
Lingappa JR, Lambdin B, Bukusi EA, Ngure K, Kavuma L, Inambao M, et al. Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. PLoS One. 2008;3(1):e1411.
Takassi OE, Akolly DAE, Guedenon KM, Atakouma YD. Partage du statut serologique au sein des couples serodiscordants dans un protocole de PTME en pediatrie au CHU Sylvanus Olympio (Togo). J la Rech Sci l’Université Lomé. 2020;22(1–2):243–248.
Guira O, Tieno H, Sawadogo S, Drabo JY. Sexuality and risk for sexual transmission of HIV among serodiscordant couples in Ouagadougou, Burkina Faso. Bull Soc Pathol Exot. 2013;106(1):43–47.
Sabeti PC, Walsh E, Schaffner SF, Varilly P, Fry B, Hutcheson HB, et al. The case for selection at CCR5-Δ 32. PLoS Biol. 2005;3(11):e378.
Grenfell BT, Pybus OG, Gog JR, Wood JLN, Daly JM, Mumford JA, et al. Unifying the epidemiological and evolutionary dynamics of pathogens. Science (80- ). 2004;303(5656):327–332.
Agrawal L, Lu X, Qingwen J, VanHorn-Ali Z, Nicolescu IV, McDermott DH, et al. Role for CCR5Δ32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol. 2004;78(5):2277–2287.
Guenthner PC, Hershow RC, Lal RB, Dezzutti CS. Effects of human T-lymphotropic virus type II on human immunodeficiency virus type 1 phenotypic evolution. Arch Virol. 2001;146:1617–1622.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Isaac Woto Tshikuma, Simplice Makoka Kivuvu, Charlotte Tshinguta Londji, Berry Bongenya Ikolango, Erick Kamangu Ntambwe
This work is licensed under a Creative Commons Attribution 4.0 International License.
